Biotech · Private company
Genmab
Track this companyFree. Adds Genmab to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs56From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline56
- 5-FUPhase 3 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- AcasunlimabPhase 3 · PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 3 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 3 · Platinum-Sensitive Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 3 · Platinum-Sensitive Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 3 · Left-sided Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 3 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 3 · PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- EpcoritamabPhase 3 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- FOLFIRIPhase 3 · Left-sided Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- GemcitabinePhase 3 · Platinum-Sensitive Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- GemcitabinePhase 3 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- ICPhase 3 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
- Investigator's ChoicePhase 3 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Investigator's Choice ChemotherapyPhase 3 · Diffuse Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Leucovorin (Calcium Folinate)Phase 3 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- mFOLFOX6Phase 3 · Left-sided Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- OxaliplatinPhase 3 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Platinum-Sensitive Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Pegylated liposomal doxorubicin (PLD)Phase 3 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- PetosemtamabPhase 3 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PetosemtamabPhase 3 · Left-sided Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- PetosemtamabPhase 3 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- PLDPhase 3 · Platinum-Sensitive Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Rina-SPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Rina-SPhase 3 · Endometrial CancerClinicalTrials.gov · fetched Nov 12, 2026
- Rina-SPhase 3 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Rina-SPhase 3 · Platinum-Sensitive Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- TopotecanPhase 3 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · High Grade Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · High Grade Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- EpcoritamabPhase 2 · Relapsed/Refractory Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- EpcoritamabPhase 2 · DLBCLClinicalTrials.gov · fetched Nov 12, 2026
- ErythromycinPhase 2 · High Grade Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- gemcitabine and oxaliplatinPhase 2 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- ItraconazolePhase 2 · High Grade Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- LenalidomidePhase 2 · Relapsed/Refractory Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- MCLA-158Phase 2 · Advanced/Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- MCLA-158 + FOLFIRIPhase 2 · Advanced/Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- MCLA-158 + FOLFOXPhase 2 · Advanced/Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- MCLA-158 + PembrolizumabPhase 2 · Advanced/Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · High Grade Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Rina-SPhase 2 · Gastrointestinal CancersClinicalTrials.gov · fetched Nov 12, 2026
- Rina-SPhase 2 · High Grade Epithelial Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Rina-SPhase 2 · Non-small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- rituximab and bendamustinePhase 2 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- rituximab and lenalidomidePhase 2 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- rituximab, cyclophosphamide, doxorubicin, vincristine and prednisonePhase 2 · Relapsed/Refractory Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisonePhase 2 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatinPhase 2 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 2 · Relapsed/Refractory Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- GEN1106Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphomaPHASE2 · NOT_YET_RECRUITING · started Feb 12, 2027ClinicalTrials.gov NCT07783594 · fetched Nov 12, 2026
- Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKIPHASE2 · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07819214 · fetched Nov 12, 2026
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)PHASE3 · RECRUITING · started Oct 7, 2026ClinicalTrials.gov NCT07775287 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian CancerPHASE3 · RECRUITING · started Aug 28, 2026ClinicalTrials.gov NCT07564141 · fetched Nov 12, 2026
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)PHASE3 · RECRUITING · started Aug 11, 2026ClinicalTrials.gov NCT07702032 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) CancersPHASE2 · RECRUITING · started May 11, 2026ClinicalTrials.gov NCT07539311 · fetched Nov 12, 2026
- A Study of GEN1106 in Participants With Solid TumorsPHASE1 · RECRUITING · started Apr 14, 2026ClinicalTrials.gov NCT07416123 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet ChemotherapyPHASE3 · RECRUITING · started Apr 3, 2026ClinicalTrials.gov NCT07225270 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung CancerPHASE2 · RECRUITING · started Jan 30, 2026ClinicalTrials.gov NCT07288177 · fetched Nov 12, 2026
- Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell LymphomaPHASE2 · RECRUITING · started Jan 7, 2026ClinicalTrials.gov NCT06919939 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial CancerPHASE3 · RECRUITING · started Nov 28, 2025ClinicalTrials.gov NCT07166094 · fetched Nov 12, 2026
- Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)PHASE2 · RECRUITING · started Oct 13, 2025ClinicalTrials.gov NCT06796998 · fetched Nov 12, 2026
- Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerPHASE4 · RECRUITING · started May 7, 2025ClinicalTrials.gov NCT06952660 · fetched Nov 12, 2026
- Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 7, 2025ClinicalTrials.gov NCT06619236 · fetched Nov 12, 2026
- Epco, Zanu, Ritux for R/R FL or MZLPHASE2 · RECRUITING · started Jan 21, 2025ClinicalTrials.gov NCT06563596 · fetched Nov 12, 2026
- Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)PHASE3 · ACTIVE_NOT_RECRUITING · started Nov 25, 2024ClinicalTrials.gov NCT06635824 · fetched Nov 12, 2026
- A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)PHASE3 · ACTIVE_NOT_RECRUITING · started Sep 25, 2024ClinicalTrials.gov NCT06525220 · fetched Nov 12, 2026
- A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)PHASE3 · ACTIVE_NOT_RECRUITING · started Jun 25, 2024ClinicalTrials.gov NCT06496178 · fetched Nov 12, 2026
- Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell LymphomaPHASE2 · RECRUITING · started Oct 31, 2023ClinicalTrials.gov NCT05852717 · fetched Nov 12, 2026
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)PHASE1_PHASE2 · RECRUITING · started Dec 7, 2022ClinicalTrials.gov NCT05579366 · fetched Nov 12, 2026
- A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)PHASE3 · ACTIVE_NOT_RECRUITING · started Jan 13, 2021ClinicalTrials.gov NCT04628494 · fetched Nov 12, 2026
- Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's SyndromePHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 25, 2020ClinicalTrials.gov NCT04623541 · fetched Nov 12, 2026
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 3, 2020ClinicalTrials.gov NCT04663347 · fetched Nov 12, 2026
- First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 26, 2018ClinicalTrials.gov NCT03625037 · fetched Nov 12, 2026
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started May 2, 2018ClinicalTrials.gov NCT03526835 · fetched Nov 12, 2026